Extensive fundamental research has established that EGFR exerts its oncogenic effects through activation of downstream signaling cascades, particularly the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways, which collectively drive aberrant proliferation of intestinal epithelial cells, enhance metastatic potential, and promote tumor angiogenesis [29]. This evidence concerns the gene AKT1 and neoplasm.